Trauma - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Trauma - Pipeline Review, H1 2015', provides an overview of the Trauma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Trauma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Trauma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Trauma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Trauma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Trauma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Trauma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Trauma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Trauma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Trauma Overview 6 Therapeutics Development 7 Pipeline Products for Trauma - Overview 7 Pipeline Products for Trauma - Comparative Analysis 8 Trauma - Therapeutics under Development by Companies 9 Trauma - Therapeutics under Investigation by Universities/Institutes 10 Trauma - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Trauma - Products under Development by Companies 13 Trauma - Products under Investigation by Universities/Institutes 14 Trauma - Companies Involved in Therapeutics Development 15 AstraZeneca PLC 15 Bionature E.A. Ltd. 16 Edge Therapeutics, Inc. 17 SanBio, Inc. 18 Trauma - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 EG-1962 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 MEDI-8111 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Peptide to Activate GLP1R for CNS, Metabolic Disorders and Head Trauma - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Peptides to Activate GLP-1 Receptor for CNS Disorders and Head Trauma - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 PT-00114 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 PT-00311 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 SB-308 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Small Molecules to Agonize Neurotrophin Receptor for CNS and Ophthalmological Disorders - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Synthetic Peptides to Activate SDF-1 Alpha for CNS Disorders - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 TPX-100 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Trauma - Recent Pipeline Updates 39 Trauma - Dormant Projects 41 Trauma - Discontinued Products 42 Trauma - Product Development Milestones 43 Featured News & Press Releases 43 Jun 10, 2013: Edge Therapeutics Announces FDA Accepts IND Application For EG-1962 43 Appendix 44 Methodology 44 Coverage 44 Secondary Research 44 Primary Research 44 Expert Panel Validation 44 Contact Us 45 Disclaimer 45
List of Tables Number of Products under Development for Trauma, H1 2015 7 Number of Products under Development for Trauma - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Number of Products under Investigation by Universities/Institutes, H1 2015 10 Comparative Analysis by Clinical Stage Development, H1 2015 11 Comparative Analysis by Early Stage Development, H1 2015 12 Products under Development by Companies, H1 2015 13 Products under Investigation by Universities/Institutes, H1 2015 14 Trauma - Pipeline by AstraZeneca PLC, H1 2015 15 Trauma - Pipeline by Bionature E.A. Ltd., H1 2015 16 Trauma - Pipeline by Edge Therapeutics, Inc., H1 2015 17 Trauma - Pipeline by SanBio, Inc., H1 2015 18 Assessment by Monotherapy Products, H1 2015 19 Number of Products by Stage and Target, H1 2015 21 Number of Products by Stage and Mechanism of Action, H1 2015 23 Number of Products by Stage and Route of Administration, H1 2015 25 Number of Products by Stage and Molecule Type, H1 2015 27 Trauma Therapeutics - Recent Pipeline Updates, H1 2015 39 Trauma - Dormant Projects, H1 2015 41 Trauma - Discontinued Products, H1 2015 42
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.